Jardiance effects on body weight
Pro Research Analysisby 
Searched over 200M research papers
Jardiance (Empagliflozin) and Body Weight Reduction in Type 2 Diabetes
SGLT2 Inhibitors and Weight Loss Effects
Empagliflozin (Jardiance) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. Multiple studies show that empagliflozin leads to weight loss in patients with type 2 diabetes, mainly due to its mechanism of increasing glucose excretion in urine, which results in calorie loss and subsequent reduction in body weight 12356.
Magnitude of Weight Loss with Jardiance
Clinical trials have consistently reported that empagliflozin use is associated with modest but meaningful weight loss. On average, patients experience a reduction of about 2 kg in body weight when compared to placebo or other antidiabetic medications such as metformin, glimepiride, or sitagliptin 23. This weight loss is considered an added benefit alongside improved glycemic control and reduced blood pressure 123.
Weight Loss in Special Populations
Empagliflozin has also shown weight reduction benefits in specific groups, such as cardiac transplant recipients with diabetes, without increasing the risk of adverse effects like genitourinary infections or hypoglycemia . This suggests that the weight loss effect of Jardiance is consistent across different patient populations.
Comparison with Other Weight Loss Medications
While empagliflozin and other SGLT2 inhibitors are effective for weight loss in diabetes management, they are generally less potent than glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide or tirzepatide, which are also used for weight reduction . However, empagliflozin is well tolerated and offers additional cardiovascular and renal benefits 35.
Clinical Considerations and Safety
Empagliflozin is generally safe, but it should be used with caution in patients with renal insufficiency, as its efficacy decreases in this group . The risk of severe side effects is low, but mild urinary and genital infections can occur 123. It is important to manage these risks, especially in perioperative settings, where discontinuation may be recommended to avoid complications .
Conclusion
Jardiance (empagliflozin) reliably promotes modest weight loss in patients with type 2 diabetes, typically around 2 kg, as part of its overall metabolic benefits. This effect is consistent across various patient groups and adds to its value as a diabetes treatment, especially for those also seeking weight reduction. The medication is generally well tolerated, but appropriate patient selection and monitoring are important to maximize benefits and minimize risks.
Sources and full results
Most relevant research papers on this topic